Sertoli-Leydig Cell TumorSymptoms, Doctors, Treatments, Advances & More
Learn About Sertoli-Leydig Cell Tumor
Sertoli-Leydig cell tumor (SLCT) is a rare cancer of the ovaries. The cancer cells produce and release a male sex hormone called testosterone.
Sertoli-stromal cell tumor; Arrhenoblastoma; Androblastoma; Ovarian cancer - Sertoli-Leydig cell tumor
The exact cause of this tumor is not known. Changes (alterations) in genes may play a role.
SLCT occur most often in young women 20 to 30 years old. But the tumor can occur at any age.
The Sertoli cells are normally located in the male reproductive glands (the testes). They feed sperm cells. The Leydig cells, also located in the testes, release a male sex hormone.
These cells are also found in a woman's ovaries, and in very rare cases lead to cancer. SLCT starts in the female ovaries, mostly in one ovary. The cancer cells release a male sex hormone. As a result, the woman may develop symptoms such as:
- A deep voice
- Enlarged clitoris
- Facial hair
- Loss in breast size
- Stopping of menstrual periods
Pain in the lower belly (pelvic area) is another symptom. It occurs due to the tumor pressing on nearby structures.
Surgery is done to remove one or both ovaries.
If the tumor is at an advanced stage, chemotherapy or radiation therapy may be done after surgery.
Aurora Gynecologic Oncology
Scott Kamelle is an Oncologist practicing medicine in West Allis, Wisconsin. Dr. Kamelle is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ureteroscopy, and Bladder Reconstruction. Dr. Kamelle is board certified in American Board Of Obstetrics & Gynecology, Gynecologic Oncology.
St. Vincent Regional Hospital - Cancer Centers Of Montana
Dr. Connor completed an undergraduate degree in Biochemistry at the University of Virginia and later earned her Medical Doctorate at the University of Virginia School of Medicine. She then completed her Obstetrics & Gynecology Residency training at Brown University and Gynecologic Oncology fellowship training at the Cleveland Clinic. She is board-certified in both obstetrics and gynecology and gynecologic oncology. Her clinical interests include preventing, diagnosing, and treating ovarian, uterine, cervical, vaginal and vulvar cancers. Dr. Connor moved to Montana to ensure comprehensive access to gynecologic oncology services in the region.“I care deeply for my patients and work hard for them to have the highest level of care and autonomy in their care.”When not seeing patients, Dr. Connor spends her time with her husband, two children, and two family dogs. They spend most of their time outside, whether skiing, hiking, or catching a soccer game. Dr. Connor is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Endometrial Cancer, Bladder Reconstruction, and Hysterectomy. Dr. Connor is board certified in American Board Of Obstetrics And Gynecology and American Board Of Obstetrics And Gynecology. Dr. Connor is currently accepting new patients.
Jefferson Obstetrics And Gynecology
. Dr. Rosenblum is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Vulvar Cancer, Sertoli-Leydig Cell Tumor, Hernia Surgery, and Hysterectomy. Dr. Rosenblum is board certified in American Board Of Obstetrics And Gynecology.
Early treatment results in a good outcome. Feminine characteristics usually return after surgery. But male characteristics resolve more slowly.
For more advanced stage tumors, outlook is less positive.
Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...
Background: \- Pleuropulmonary blastoma (PPB) is a rare fast-growing lung tumor that is associated with other, rare tumor types. Most cases of PPB appear in children younger than 6 years of age. Recently, it has been shown that this condition can be inherited (e.g., mutation of the DICER1 gene). Researchers are studying both clinical and genetic aspects of this newly described condition. They are interested i...
Published Date: June 17, 2024
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Beffa LB, Sung CJ, DiSilvestro PA. Germ cell, stromal, and other ovarian tumors. In: Creasman WT, Mutch DG, Mannel RS, Tewari KS, eds. DiSaia and Creasman Clinical Gynecologic Oncology. 10th ed. Philadelphia, PA: Elsevier; 2023:chap 10.
Fletcher CDM. Tumors of the female genital tract. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 5th ed. Philadelphia, PA: Elsevier; 2021:chap 13.
Smith RP. Sertoli-Leydig cell tumor (arrhenoblastoma). In: Smith RP, ed. Netter's Obstetrics & Gynecology. 4th ed. Philadelphia, PA: Elsevier; 2024:chap 165.